Depression occurs in approximately 45%of all patients with Parkinsons disea se (PD), reduces quality of life independent of motor symptoms and seems to be u nderrated and undertreated. Characteristics of symptoms di...Depression occurs in approximately 45%of all patients with Parkinsons disea se (PD), reduces quality of life independent of motor symptoms and seems to be u nderrated and undertreated. Characteristics of symptoms differ from major depres sion. Because of overlapping clinical symptoms, diagnosis is based on subjective ly experienced anhedonia and feeling of emptiness. Available rating scales for m ajor depression may not be adequate to correctly measure severity of depression in PD. Anxiety and depression may manifest as first symptoms of PD many years be fore motor symptoms. Serotonergic, noradrenergic and dopaminergic mechanisms pla y key roles in the etiology of depression in PD. Tricyclic and newer, selective antidepressants including serotonin and noradrenaline reuptake inhibitors (SSRI, SNRI) appear to be effective in treating depression in PD. Selective reuptake i nhibitors seem to have a favorable side effect profile. Recent controlled studie s show antidepressant effects of pramipexole in bipolar II depression. New dopam ine agonists pramipexole and ropinirole appear to ameliorate depressive symptoms in PD in addition to effects on motor symptoms. There is a lack of appropriate rating scales and controlled studies regarding depression in PD.展开更多
文摘Depression occurs in approximately 45%of all patients with Parkinsons disea se (PD), reduces quality of life independent of motor symptoms and seems to be u nderrated and undertreated. Characteristics of symptoms differ from major depres sion. Because of overlapping clinical symptoms, diagnosis is based on subjective ly experienced anhedonia and feeling of emptiness. Available rating scales for m ajor depression may not be adequate to correctly measure severity of depression in PD. Anxiety and depression may manifest as first symptoms of PD many years be fore motor symptoms. Serotonergic, noradrenergic and dopaminergic mechanisms pla y key roles in the etiology of depression in PD. Tricyclic and newer, selective antidepressants including serotonin and noradrenaline reuptake inhibitors (SSRI, SNRI) appear to be effective in treating depression in PD. Selective reuptake i nhibitors seem to have a favorable side effect profile. Recent controlled studie s show antidepressant effects of pramipexole in bipolar II depression. New dopam ine agonists pramipexole and ropinirole appear to ameliorate depressive symptoms in PD in addition to effects on motor symptoms. There is a lack of appropriate rating scales and controlled studies regarding depression in PD.
